Download and Immune Response - Drug Discovery Digest

Drug repurposing in SARS-CoV-2 / COVID-19: preventing the maladaptive immune response leading to critical disease requiring ICU care.

Plenge Gen

APRIL 7, 2020

You can download a pdf copy of the blog here.) Here, I focus on a specific clinical inflection point in COVID-19 disease progression – hospitalized patients early in their disease course and with signs of a maladaptive immune response, with the intervention intended to prevent disease progression and admission to the ICU.

Immune Response

Immune Response Disease Clinical Trials Drugs

Case study: gget’s new Open Target module

The Open Targets Blog

JANUARY 30, 2025

For example, to find drugs associated with the human IL13 gene (Ensembl ID ENSG00000169194*), a cytokine that plays an important role in allergic inflammation and immune response to parasite infection, you can use: # Install gget !pip Where do you think the limits of this application are?

Bioinformatics

Bioinformatics Immune Response RNA Packaging

New electronic survey manual supports countries to combat micronutrient deficiencies

The Pharma Data

OCTOBER 15, 2020

Micronutrients are critical for a well-functioning immune system, which is of utmost importance during the COVID-19 pandemic. There is also a downloadable platform that functions like the website such that resources can be accessible to users offline.

Immune Response

Immune Response International Government Research

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Keeping tabs on Covid-19: Thermo Fisher Scientific antibody test is granted the CE Mark Certification and pharma cargo companies prepare for temperature-controlled vaccine delivery

The Pharma Data

DECEMBER 11, 2020

Thermo Fisher joined forces with the University of Oxford to harness its academic research capabilities in quantifying IgG antibodies and understanding each patient’s immune response to SARS-CoV-2.

Vaccine

Vaccine Immune Response Pharma Companies Virus

ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology

The Pharma Data

JANUARY 6, 2021

CD8 T cells are the main effector cells involved in the immune response against tumor cells induced by immunotherapies and they also play a key role in multiple autoimmune diseases. View original content to download multimedia: [link].

Licensing

Licensing Licensing Clinical Trials Pharmaceutical Companies

Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. View original content to download multimedia: [link]. CHENGDU, China , Feb. SOURCE Clover Biopharmaceuticals. Source link.

Clinical Trials

Clinical Trials Vaccine Trials Virus

Keeping tabs on Covid-19: UK firm tests oral delivery of Covid-19 vaccine and Novavax aims to distribute 51 million vaccines to Australia

The Pharma Data

JANUARY 22, 2021

Novavax’s vaccine is a recombinant protein vaccine adjuvanted with Novavax’s nanoparticle technology, Matrix-M, which enhances immune response in recipients. Download this exclusive report here.

Vaccine

Vaccine Immune Response Government RNA

Cytiva supports Clover Biopharmaceuticals to scale up the output of its vaccine candidate

The Pharma Data

NOVEMBER 15, 2020

As the first company in the world to produce a COVID-19 vaccine candidate that is successfully recognized by antibodies produced by previously-infected patients, Clover demonstrates that S-Trimer has preserved the native structure of the viral spike (S) protein and thus may elicit a protective-immune response as a vaccine.

Vaccine

Vaccine Immune Response Clinical Trials Science

Moleculin Announces Annamycin Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas

The Pharma Data

DECEMBER 28, 2020

Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related compounds capable of Metabolism/Glycosylation Inhibition. View original content to download multimedia: [link]. . .

FDA

FDA Clinical Trials Drugs Pharmaceutical Companies

Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate

The Pharma Data

JANUARY 31, 2021

Clover’s S-Trimer antigen adjuvanted with CpG 1018 plus alum demonstrated low reactogenicity while providing high levels of neutralizing antibodies and a strong Th1-biased cell-mediated immune response. Dynavax developed CpG 1018 to provide an increased vaccine immune response, which has been demonstrated in HEPLISAV-B.

Vaccine

Vaccine Trials Virus RNA

Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock – Oct 28, 2020

The Pharma Data

OCTOBER 27, 2020

Sitravatinib is an investigational spectrum-selective inhibitor of receptor tyrosine kinases (RTK) designed to enhance immune responses through the inhibition of immunosuppressive signaling. View original content to download multimedia: [link]. SOURCE Mirati Therapeutics, Inc. Company Codes: NASDAQ-SMALL:MRTX.

Small Molecule

Small Molecule Immune Response Clinical Development Clinical Trials

Moleculin Announces Independent Study Validates Annamycin’s Ability to Target Lung Localized Tumors

The Pharma Data

OCTOBER 20, 2020

Moleculin is also engaged in preclinical development of additional drug candidates, including other Immune/Transcription Modulators, as well as WP1122 and related compounds capable of Metabolism/Glycosylation Inhibition. View original content to download multimedia: [link]. . .

Clinical Trials

Clinical Trials Pharmaceutical Companies Treatment Immune Response

Tezepelumab NAVIGATOR Phase 3 Trial Met Primary Endpoint Of A Statistically Significant And Clinically Meaningful Reduction In Exacerbations In A Broad Population Of Patients With Severe Asthma

The Pharma Data

NOVEMBER 9, 2020

Specifically, tezepelumab targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma. View original content to download multimedia: [link].

Trials

Trials Production Clinical Trials Government

Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma

The Pharma Data

DECEMBER 21, 2020

Specifically, tezepelumab targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma. View original content to download multimedia: [link].

Trials

Trials Production Clinical Trials Therapies

Scientists work out the effects of exercise at the cellular level

Broad Institute

MAY 1, 2024

Other scientists can use this site to download, for example, information about the proteins changing in abundance in the lungs of female rats after eight weeks of regular exercise on a treadmill, or the RNA response to exercise in all organs of male and female rats over time.

RNA

RNA Regulations Immune Response Disease

Apexigen’s APX005M Granted Orphan Drug Designations for the Treatment of Esophageal and Gastroesophageal Junction Cancer and for the Treatment of Pancreatic Cancer

The Pharma Data

OCTOBER 14, 2020

APX005M is a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response. APX005M targets CD40, a co-stimulatory receptor that is essential for activating both innate and adaptive immune systems. View original content to download multimedia: [link]. Apexigen Contact: Mark Nevins Sr.

Treatment

Treatment Immune Response Clinical Trials Clinical Development

FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine

The Pharma Data

DECEMBER 18, 2020

After a person receives this vaccine, their body produces copies of the spike protein, which does not cause disease, but triggers the immune system to learn to react defensively, producing an immune response against SARS-CoV-2. View original content to download multimedia: [link]. SOURCE U.S. Food and Drug Administration.

Vaccine

Vaccine FDA Clinical Trials FDA Approval

Codon Digest: Vaccine Printer Go Brrrrr!

Codon

APRIL 30, 2023

In one experiment, the microneedle patches were used to deliver a SARS-CoV-2 vaccine into mice, producing immune responses similar to a traditional injection. Printed vaccines caused mice to have a faster immune response. But the printed vaccines are very good! Nucleic Acids Research.

Vaccine

Vaccine DNA Engineering RNA

Codon Digest: Vaccine Printer Go Brrrrr!

Codon

APRIL 30, 2023

In one experiment, the microneedle patches were used to deliver a SARS-CoV-2 vaccine into mice, producing immune responses similar to a traditional injection. Printed vaccines caused mice to have a faster immune response. But the printed vaccines are very good! Nucleic Acids Research.

Vaccine

Vaccine DNA Engineering RNA

Scaling Phage Therapy

Codon

FEBRUARY 13, 2024

Such contaminants could have the same toxic effects as the bacterial infection, or provoke a severe immune response in the patient, and therefore the phage mixtures must go through extensive purification and testing procedures. This process would begin by taking a sample of bacteria from the patient and sequencing its DNA.

Therapies

Therapies Virus DNA Clinical Trials

BioInvent and Transgene receive CTA approval for Phase l/lla trial of oncolytic virus BT-001 in solid tumors

The Pharma Data

DECEMBER 20, 2020

This oncolytic virus has induced long-lasting antitumor immune responses and abscopal effects in several tumor models, and its activity is further enhanced through combination with an anti-PD-1 antibody treatment. The following files are available for download: View original content: [link]. SOURCE BioInvent.

Virus

Virus Trials Clinical Trials Clinical Development

Transgene Announces Detailed Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-positive Cancers

The Pharma Data

OCTOBER 26, 2020

Following the unauthorized download of all abstracts on the SITC website, Transgene is communicating the content of the late-breaking poster abstract that will be presented at the SITC 35th Anniversary Annual Meeting (SITC 2020), to be held virtually November 9-14, 2020.

Vaccine

Vaccine Trials Treatment Virus

Dynavax Announces Final Immunogenicity and Interim Safety Results from Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing Hemodialysis

The Pharma Data

JANUARY 6, 2021

. About HEPLISAV-B HEPLISAV-B is an adult hepatitis B vaccine that combines hepatitis B surface antigen with Dynavax’s proprietary Toll-like Receptor (TLR) 9 agonist adjuvant CpG 1018 to enhance the immune response. View original content to download multimedia: [link]. ii CDC.

Clinical Trials

Clinical Trials Trials Vaccine Immune Response

Drug Discovery Digest

Drug repurposing in SARS-CoV-2 / COVID-19: preventing the maladaptive immune response leading to critical disease requiring ICU care.

Case study: gget’s new Open Target module

Webinars

Trending Sources

New electronic survey manual supports countries to combat micronutrient deficiencies

Webinars

Keeping tabs on Covid-19: Thermo Fisher Scientific antibody test is granted the CE Mark Certification and pharma cargo companies prepare for temperature-controlled vaccine delivery

ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology

Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet

Keeping tabs on Covid-19: UK firm tests oral delivery of Covid-19 vaccine and Novavax aims to distribute 51 million vaccines to Australia

Cytiva supports Clover Biopharmaceuticals to scale up the output of its vaccine candidate

Moleculin Announces Annamycin Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas

Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate

Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock – Oct 28, 2020

Moleculin Announces Independent Study Validates Annamycin’s Ability to Target Lung Localized Tumors

Tezepelumab NAVIGATOR Phase 3 Trial Met Primary Endpoint Of A Statistically Significant And Clinically Meaningful Reduction In Exacerbations In A Broad Population Of Patients With Severe Asthma

Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma

Scientists work out the effects of exercise at the cellular level

Apexigen’s APX005M Granted Orphan Drug Designations for the Treatment of Esophageal and Gastroesophageal Junction Cancer and for the Treatment of Pancreatic Cancer

FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine

Codon Digest: Vaccine Printer Go Brrrrr!

Codon Digest: Vaccine Printer Go Brrrrr!

Scaling Phage Therapy

BioInvent and Transgene receive CTA approval for Phase l/lla trial of oncolytic virus BT-001 in solid tumors

Transgene Announces Detailed Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-positive Cancers

Dynavax Announces Final Immunogenicity and Interim Safety Results from Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing Hemodialysis

Stay Connected